We are monitoring the impact of COVID-19 & Recession alarm on Checkpoint Inhibitors Market Get in touch with us for detailed analysis Know More
Share on

Global Checkpoint Inhibitors Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type (PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell and others), Application & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 2084
Pages: 175

Global Checkpoint Inhibitors Market Size (2022 to 2027)

The size of the global checkpoint inhibitors market is estimated to be growing at a CAGR of 28.68% during the forecast period. The size of the market is predicted to value USD 58.57 billion by 2027 from USD 16.60 billion in 2022.

Checkpoint Inhibitors are drugs used in Immunotherapy. They are generally made up of antibodies that lead to an immune system attack on cancer cells. T-cells launch an attack when it detects infected or Cancerous. The immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells, which lets T-Cells launch an attack on cancer cells.

Rising Prevalence of cancer globally and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the Checkpoint Inhibitors Market.

Some of the other prominent factors that drive the growth of the global checkpoint inhibitors market are increased funds, government support in developing new drugs, and frequent rise in cancer. Precision in medicine will be a significant driver for pharmaceuticals to deliver innovative medicines. There is an extreme competition force in checkpoint inhibitors, which is driving the learning or developing skill and in-license agreements. It is also driven by research developments made by learning institutes and industry contributors. By affecting the cost of the nation, there is a need to address the day to day increase of cancer prevalence.

A comprehensive analysis of regions is to provide current opportunities. It also offers a quantitative study to enable the stakeholders to make a massive amount in market opportunities.

The high cost involved in research and development is one of the major factors restraining the global checkpoint inhibitors market. Also, the lack of awareness and proper publicity for the use of these inhibitors, especially in the developing regions, are acting as deterrents for expanding the global checkpoint inhibitors market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Analysed

By Drug, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Analysed

Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma

 

This research report on the global checkpoint inhibitors market has been segmented and sub-segmented based on the drug, application, and region.

Checkpoint Inhibitors Market - By Drug:

  • PD-1 inhibitors
  • PD-L1 inhibitors
  • CTLA-4
  • Chimeric Antigen Receptor T-cell
  • Others

The CTLA-4 segment holds the highest share based on drugs, accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market shares to the PD-1 inhibitors segment during the forecast period, as most new treatments are based on PD-1 inhibitors.

Checkpoint Inhibitors Market - By Application:

  • Lung Cancer
  • Renal Cancer
  • Blood Cancer
  • Bladder Cancer
  • Hodgkin Lymphoma
  • Melanoma
  • Others

Checkpoint Inhibitors Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America dominates the global checkpoint inhibitors market, owing to high clinics and the availability of funds. But, APAC, i.e., Asia-Pacific, is the fastest-growing region. In this region, international players collaborate with local companies. Asia-Pacific produces a great deal of profit for the key players operating in the immune checkpoint inhibitors market, which is supported by its large population and their awareness about the immune therapy, etc. 

Latin America and Middle East & Africa are also expected to produce a great deal of profit for the key players during the forecast period. Due to healthcare development, there will be a rise in demand for the checkpoint inhibitors market in all parts of the world.

KEY MARKET PLAYERS:

Notable companies leading the global checkpoint inhibitors market covered in this report are Merck & Co. Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd, Juno Therapeutics, Novartis International AG, and Kite Pharma.

RECENT MARKET HAPPENINGS :

  • In February 2019, Merck & Co., Inc. has announced that they had received US FDA approval for the checkpoint inhibitor “Keytruda,” which is used for the treatment of Merkel cell carcinoma.
  • For the treatment of non-small cell lung cancer in advanced stages, the F. Hoffmann-La Roche Ltd. announced in January 2019 that they received US FDA approval for “Tecentriq, in combination with bevacizumab, paclitaxel, and carboplatin.
  • In October 2018, for the treatment of advanced cutaneous squamous cell carcinoma, Regeneron announced that they had received US FDA approval for “Libtayo.”

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 PD-1 inhibitors       

                                5.1.3 PD-L1 inhibitors     

                                5.1.4 CTLA-4      

                                5.1.5  Chimeric Antigen Receptor T-cell 

                                5.1.6  Others     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type           

                                5.1.8 Market Attractiveness Analysis, By Drug Type         

                                5.1.9 Market Share Analysis, By Drug Type          

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Lung cancer            

                                5.2.3 Renal cancer           

                                5.2.4 Blood cancer          

                                5.2.5 Bladder Cancer      

                                5.2.6  Hodgkin lymphoma            

                                5.2.7 Melanoma              

                                5.2.8  Others     

                                5.2.9 Y-o-Y Growth Analysis, By Application         

                                5.2.10  Market Attractiveness Analysis, By Application   

                                5.2.11  Market Share Analysis, By Application     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                                6.1.3.3 By Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                                6.1.4.3 By Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Type

                                                6.1.5.3 By Application

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Merck & Co., Inc.                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 Roche                           

                8.4 AstraZeneca                               

                8.5 Ono Pharmaceutical Co., Ltd.                              

                8.6  Juno Therapeutics                  

                8.7 Novartis International AG                    

                8.8 Kite Pharma                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Global Checkpoint Inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  2. Global Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  3. Global PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  4. Global PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  5. Global CTLA-4 Market, By Region, From 2022 - 2027 (USD Billion)
  6. Global Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Billion)
  7. Global Others Market, By Region, From 2022 - 2027 (USD Billion)
  8. Global Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  9. Global Lung cancer Market, By Region, From 2022 - 2027 (USD Billion)
  10. Global Renal cancer Market, By Region, From 2022 - 2027 (USD Billion)
  11. Global Blood cancer Market, By Region, From 2022 - 2027 (USD Billion)
  12. Global Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  13. Global Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Billion)
  14. Global Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  15. Global Others Market, By Region, From 2022 - 2027 (USD Billion)
  16. North America Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  17. North America PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  18. North America PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  19. North America CTLA-4 Market, By Region, From 2022 - 2027 (USD Billion)
  20. North America Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Billion)
  21. North America Others Market, By Region, From 2022 - 2027 (USD Billion)
  22. North America Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  23. North America Lung cancer Market, By Region, From 2022 - 2027 (USD Billion)
  24. North America Renal cancer Market, By Region, From 2022 - 2027 (USD Billion)
  25. North America Blood cancer Market, By Region, From 2022 - 2027 (USD Billion)
  26. North America Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  27. North America Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Billion)
  28. North America Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  29. North America Others Market, By Region, From 2022 - 2027 (USD Billion)
  30. United States Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  31. United States Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  32. Canada Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  33. Canada Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  34. Europe Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  35. Europe PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  36. Europe PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  37. Europe CTLA-4 Market, By Region, From 2022 - 2027 (USD Billion)
  38. Europe Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Billion)
  39. Europe Others Market, By Region, From 2022 - 2027 (USD Billion)
  40. Europe Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  41. Europe Lung cancer Market, By Region, From 2022 - 2027 (USD Billion)
  42. Europe Renal cancer Market, By Region, From 2022 - 2027 (USD Billion)
  43. Europe Blood cancer Market, By Region, From 2022 - 2027 (USD Billion)
  44. Europe Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  45. Europe Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Billion)
  46. Europe Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  47. Europe Others Market, By Region, From 2022 - 2027 (USD Billion)
  48. U.K. Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  49. U.K. Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  50. Germany Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  51. Germany Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  52. France Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  53. France Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  54. Italy Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  55. Italy Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  56. Spain Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  57. Spain Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  58. Asia-Pacific Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  59. Asia-Pacific PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  60. Asia-Pacific PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  61. Asia-Pacific CTLA-4 Market, By Region, From 2022 - 2027 (USD Billion)
  62. Asia-Pacific Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Billion)
  63. Asia-Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
  64. Asia-Pacific Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  65. Asia-Pacific Lung cancer Market, By Region, From 2022 - 2027 (USD Billion)
  66. Asia-Pacific Renal cancer Market, By Region, From 2022 - 2027 (USD Billion)
  67. Asia-Pacific Blood cancer Market, By Region, From 2022 - 2027 (USD Billion)
  68. Asia-Pacific Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  69. Asia-Pacific Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Billion)
  70. Asia-Pacific Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  71. Asia-Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
  72. Japan Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  73. Japan Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  74. China Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  75. China Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  76. India Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  77. India Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  78. Australia Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  79. Australia Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  80. South Korea Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  81. South Korea Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  82. Latin America Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  83. Latin America PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  84. Latin America PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  85. Latin America CTLA-4 Market, By Region, From 2022 - 2027 (USD Billion)
  86. Latin America Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Billion)
  87. Latin America Others Market, By Region, From 2022 - 2027 (USD Billion)
  88. Latin America Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  89. Latin America Lung cancer Market, By Region, From 2022 - 2027 (USD Billion)
  90. Latin America Renal cancer Market, By Region, From 2022 - 2027 (USD Billion)
  91. Latin America Blood cancer Market, By Region, From 2022 - 2027 (USD Billion)
  92. Latin America Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  93. Latin America Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Billion)
  94. Latin America Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  95. Latin America Others Market, By Region, From 2022 - 2027 (USD Billion)
  96. Brazil Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  97. Brazil Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  98. Argentina Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  99. Argentina Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  100. Mexico Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  101. Mexico Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  102. Rest of Latin America Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  103. Rest of Latin America Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  104. Middle East & Africa Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  105. Middle East & Africa PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  106. Middle East & Africa PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Billion)
  107. Middle East & Africa CTLA-4 Market, By Region, From 2022 - 2027 (USD Billion)
  108. Middle East & Africa Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Billion)
  109. Middle East & Africa Others Market, By Region, From 2022 - 2027 (USD Billion)
  110. Middle East & Africa Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  111. Middle East & Africa Lung cancer Market, By Region, From 2022 - 2027 (USD Billion)
  112. Middle East & Africa Renal cancer Market, By Region, From 2022 - 2027 (USD Billion)
  113. Middle East & Africa Blood cancer Market, By Region, From 2022 - 2027 (USD Billion)
  114. Middle East & Africa Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  115. Middle East & Africa Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Billion)
  116. Middle East & Africa Melanoma Market, By Region, From 2022 - 2027 (USD Billion)
  117. Middle East & Africa Others Market, By Region, From 2022 - 2027 (USD Billion)
  118. Middle East Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  119. Middle East Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)
  120. Africa Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Billion)
  121. Africa Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

4255


pdf excel
$

5060


pdf excel powerbi
$

7360


excel
$

2500

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 4255

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample